1. Home
  2. SABS vs ARL Comparison

SABS vs ARL Comparison

Compare SABS & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

N/A

Current Price

$3.85

Market Cap

288.8M

Sector

Health Care

ML Signal

N/A

Logo American Realty Investors Inc.

ARL

American Realty Investors Inc.

HOLD

Current Price

$14.48

Market Cap

233.9M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
SABS
ARL
Founded
2014
1999
Country
United States
United States
Employees
86
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building operators
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
288.8M
233.9M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
SABS
ARL
Price
$3.85
$14.48
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$10.75
N/A
AVG Volume (30 Days)
996.7K
2.0K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
206.59
EPS
N/A
N/A
Revenue
N/A
$50,014,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.70
52 Week Low
$1.60
$12.42
52 Week High
$6.60
$20.00

Technical Indicators

Market Signals
Indicator
SABS
ARL
Relative Strength Index (RSI) 52.16 56.25
Support Level $3.54 $12.64
Resistance Level $4.11 $16.76
Average True Range (ATR) 0.35 0.52
MACD 0.01 0.16
Stochastic Oscillator 37.74 83.32

Price Performance

Historical Comparison
SABS
ARL

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

About ARL American Realty Investors Inc.

American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.

Share on Social Networks: